Latus Bio Unveils AAV-Ep+ Capsid Variant Capable of Unprecedented Protein Production in the Brain
PHILADELPHIA--(BUSINESS WIRE)-- Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, has announced new research published today in Science Translational Medicine, 'AAVs engineered for robust brain transduction drive therapeutically relevant expression of secreted recombinant protein in NHPs and a mouse model of lysosomal storage disease.'
"This breakthrough in AAV capsid engineering represents a critical advancement in the field of gene therapy," said Dr. Beverly Davidson, Chair of the Scientific Advisory Board of Latus Bio and corresponding author of the study.
The study, led by Latus founder Beverly Davidson, PhD details the development of a novel adeno-associated virus (AAV) capsid variant - AAV-Ep+ - that demonstrates unprecedented potency in transducing cells that line the ventricles, known as ependymal cells, and cerebral neurons in mice and in non-human primates (NHPs). This advancement is potentially a significant leap forward for therapeutic gene delivery, wherein the study authors demonstrate that cells transduced with AAV-Ep+ can effectively serve as protein production depots, secreting large amounts of soluble proteins into the cerebral spinal fluid (CSF) for uptake throughout the central nervous system (CNS). This potency and distribution profile could potentially result in one-time delivery of gene therapies that encode protein treatments for lysosomal storage disorders (LSDs) as well as for other neurodevelopmental and neurodegenerative diseases that result in long term benefits for patients.
The AAV-Ep+ capsid variant was identified through a massively parallelled and unbiased screen of a large-diversity AAV variant library administered to NHPs. The nominated capsid, which was isolated from tens of millions of potential candidates, displays:
Remarkable tropism for cells that line the ventricular system of the brain and spinal cord of adult NHPs and mice. It also efficiently transduces neurons in cortical regions of the brain that are implicated in many diseases.
Robust transduction of induced pluripotent stem cell (iPSC)-derived human neurons and mice when compared to naturally occurring AAV serotypes. This cross-species activity highlights the potential for AAV-Ep+ to deliver sustained and therapeutic expression of encoded proteins in human brain cells that could result in prolonged therapeutic benefit for patients.
Low dose administration of AAV-Ep+ constructs designed to express human tripeptidyl peptidase (hTPP1) to mice deficient in TPP1 (a model of human CLN2 disease - a type of LSD) as well as to NHPs result in CSF and parenchymal tissue levels that exceeded those obtained with natural serotype capsids, reaching levels that are potentially multi-fold above therapeutic values required for CLN2 patients.
"This breakthrough in AAV capsid engineering represents a critical advancement in the field of gene therapy," said Dr. Beverly Davidson, Chair of the Scientific Advisory Board of Latus Bio and corresponding author of the study. "AAV-Ep+ offers a highly efficient, low-dose solution for brain-wide protein delivery, opening new possibilities for treating neurodevelopmental diseases like CLN2 disease and beyond."
The study showcases Latus' unique capsid discovery platform and ability to identify AAV capsid variants that are optimized for delivery to specific tissues and cell types, seeking to address translational shortcomings to prospectively enable better gene therapies. Latus continues to advance its pipeline of novel AAV capsid variants that target disease-relevant cell types in other regions of the central nervous system (e.g., cortex, cerebellum, spinal cord) as well as in peripheral tissues (e.g., ear, eye, heart, kidney and muscle). The Company is developing cutting-edge gene therapies that aim to transform the treatment landscape of genetically defined diseases, including many with high unmet medical needs.
About Latus Bio (Latus)
Latus is a biotechnology company dedicated to addressing devastating CNS and peripheral diseases via gene therapy. The Company is advancing an innovative therapeutics pipeline based on novel AAV capsid variants with potency and specificity. Latus is powered by a diverse team of visionary scientists, experienced clinicians, and leading industry executives. The Company has offices in Philadelphia, PA and in the Seaport in Boston, MA.
For more information, visit www.latusbio.com and follow on LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
3 days ago
- Business Wire
Clinical Milestones, Vector Innovation Key to Gene Therapy, GenoTher Biocluster's First International Summit,
PARIS--(BUSINESS WIRE)--Genethon, a unique non-profit gene therapy R&D organization founded by the French Muscular Dystrophy Association (AFM-Telethon), and its spin-off Atamyo Therapeutics made significant advances in their gene therapies for multiple rare diseases as highlighted in Genethon's most recent Newsletter. Chief among them are key clinical milestones reached, including those reflected in Genethon's Phase 3 ready Duchene muscular dystrophy gene therapy (GNT0004); and Atamyo's significant milestones in clinical trials of gene therapies (ATA-100 and ATA-200) for treatment of two subtypes of limb-girdle muscular dystrophy (LGMD2I/R9 and LGMD2C/R5). In addition, the GenoTher Biocluster, a public-private partnership serving as a leading ecosystem for generation of innovative genetic medicines' approaches, held its first international summit attended by 350 researchers, investors, biotech executives and public decision-makers representing more than 100 organizations. In his CEO Commentary, Genethon's Frederic Revah discusses new research involving the organization's AAV platform to increase safety, efficacy and disease applications of gene therapies. Dr. Revah reports Genethon also is exploring non-viral based delivery systems, such as Lipid Nano Particles (LNPs), for their potential in gene editing. Atamyo in April completed the dose escalation phase of a Phase 1b/2b trial in Europe of ATA-100 for LGMD2I/R9 and announced in June dosing in the US of the first two patients in a Phase 1b/2 study of ATA-200 for LGMD2C/R5. Both subtypes lead to loss of ambulation and other complications in children and there are no cures. Read the full Newsletter to learn about these gene therapy advances and others. About Genethon As a pioneer in the discovery and development of gene therapies for rare diseases, Genethon is a non-profit laboratory that was established by AFM-Telethon. A first gene therapy for spinal muscular atrophy to which Genethon contributed has obtained a product license. With more than 200 scientists and professional staff, Genethon is pursuing its aim to develop therapies which change the lives of patients suffering from rare genetic diseases. Thirteen products stemming from Genethon's R&D or from collaborations are in clinical trial for diseases of the liver, blood, immune system, muscles and eyes. Seven other products could enter clinical trials over the next five years. More information at
Yahoo
4 days ago
- Yahoo
Dr. James Y. Wang Joins Epicutis as Chairman of the Scientific Advisory Board
Harvard-Trained Dermatologist Brings Expertise to Biotech Skin Health Brand IRVINE, Calif., June 18, 2025 /PRNewswire/ -- Epicutis, a pioneering biotech skincare brand known for its science-backed, clean formulations that prioritize skin health over beauty, proudly announces the appointment of Dr. James Y. Wang as Chairman of its Scientific Advisory Board. As a Harvard and UCLA-trained double board-certified dermatologist and dermatopathologist, Dr. Wang brings a wealth of expertise in medical and aesthetic dermatology, reinforcing Epicutis' mission to deliver clinically advanced, non-toxic skincare solutions to market. James Y. Wang, MD, Founder of Metropolis Dermatology, with five locations in California, is widely recognized as a leader in dermatology, specializing in the diagnosis and treatment of skin cancers, psoriasis, eczema, and acne. His impressive academic background includes graduating summa cum laude and Phi Beta Kappa in biology from Washington University in St. Louis, followed by earning his MD from Harvard Medical School and an MBA in healthcare policy from Harvard Business School. "As a physician, I am committed to evidence-based skincare that is not only safe for all skin types but also effective," shares Dr. Wang. "Epicutis represents the perfect fusion of biotechnology and dermatological science, delivering formulations that truly transform skin health at a cellular level, and I am honored to contribute to this next chapter of innovation." Epicutis was founded on the principles of biotech-driven skincare, leveraging the research of Dr. Jeffrey Stock, a distinguished biophysicist and Princeton University professor. By harnessing proprietary, patented active ingredients, Epicutis formulates small-batch, high-performance skincare products available exclusively through skin professionals. With a focus on transparency, efficacy, and the elimination of unnecessary additives and stabilizers, the brand continues to set new standards in professional skincare. "We are thrilled to have Dr. Wang join us as Chairman of our Scientific Advisory Board," said Maxwell Stock, Founder and CEO of Epicutis. "His deep understanding of dermatological science and passion for cutting-edge innovation align perfectly with our mission to clean up the skincare industry and support clinicians with science-backed, 100% non-toxic products that make a true impact on skin health." With Dr. Wang's leadership, Epicutis is advancing its commitment to safe, biotech-driven skincare solutions while championing higher regulation to ensure safety and efficacy in an industry often dominated by misleading marketing and mass production. By prioritizing science-backed formulations with patented, highly concentrated therapeutic ingredients, Epicutis is empowering skincare professionals to stand a chance against big beauty. More than just providing innovative products – the brand is actively investing in its partners' success, helping aesthetic businesses grow with exclusive, clinical-grade solutions that drive real results and build lasting patient trust. For more information on Epicutis and its revolutionary approach to skincare, visit About EpicutisEpicutis is a science-based, luxury professional skincare line that treats skin health and not age. Honoring a commitment to clean beauty and fewer ingredients, Epicutis offers science-based skincare using patented active ingredients in small-batch formulations created by expert formulator Masanori Tamura. Epicutis' novel ingredients are developed in-house by a team of scientists at Signum Biosciences utilizing technology discovered by Dr. Jeffry Stock at Princeton University. Signum Biosciences is a biopharmaceutical company focused on the discovery and development of innovative products to address major consumer and medical needs, and the development of compounds and botanical extracts that are mimetics of natural lipid ligands crucial to cellular regulation and signaling. To learn more about Epicutis, visit To learn more about Signum Biosciences, visit View original content to download multimedia: SOURCE Epicutis Skincare Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Yahoo
Rarecells, Inc. Appoints Dr. Rita Shaknovich to Scientific Advisory Board
NEW YORK and PARIS, June 18, 2025 (GLOBE NEWSWIRE) -- Rarecells, Inc., a leader in liquid biopsy technology, is pleased to announce the appointment of Dr. Rita Shaknovich to its Scientific Advisory Board. Dr. Shaknovich brings over 20 years of leadership experience across private industry and academia. She has a distinguished track record of building high-performing teams, developing innovative diagnostic tests, establishing world-class laboratory environments, and advancing critical research in cancer biology, genomics, and Shaknovich currently serves as Chief Medical Officer at Agilent Technologies, where she oversees medical strategy and contributes to the development of innovative diagnostic solutions. Prior to joining Agilent, Dr. Shaknovich held senior leadership positions at GRAIL and Cancer Genetics, where she played pivotal roles in clinical and translational initiatives. She began her career in academic medicine, serving as Assistant Professor at Weill Cornell Medical College and Montefiore Medical Center (NY). "We are honored to welcome Dr. Shaknovich to our Scientific Advisory Board," said Dr. Patrizia Paterlini, CEO and Founder of Rarecells, Inc. "Her extensive expertise in molecular pathology and her commitment to advancing cancer diagnostics align perfectly with Rarecells' mission to revolutionize early cancer detection through innovative liquid biopsy technologies." Rarecells, Inc. is renowned for its ISET® (Isolation by SizE of Tumor cells) technology, a cutting-edge approach that enables the detection of circulating tumor cells (CTCs) and CTC-DNA in the bloodstream, facilitating early cancer diagnosis and monitoring. The addition of Dr. Shaknovich to the Scientific Advisory Board underscores the company's dedication to integrating top-tier scientific insights into its research and development efforts. "I am excited to join Rarecells' Scientific Advisory Board and contribute to their groundbreaking work in liquid biopsy," said Dr. Shaknovich. "Early detection is crucial in the fight against cancer, and I look forward to collaborating with the team to advance technologies that can significantly impact patient outcomes." About Rarecells, Inc. Rarecells, Inc. is a leading company in the development of innovative non-invasive tests for early cancer diagnosis based on the proprietary hypersensitive approaches of combined CTC-DNA, ctDNA molecular detection and AI-based Circulating Tumor Cells (CTCs) identification. Founded in 2012, the firm is headquartered in New York with offices and laboratories in New York and Paris. For more information, visit A photo accompanying this announcement is available at CONTACT: Contact: media@
